[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hiv---human-immunodeficiency-virus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hiv---human-immunodeficiency-virus":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,84,112,141,176,204],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100644404","coronary-artery-calcium-score-in-hiv-mexican-population-the-cacshivmex-study-100644404",false,"NCT07662161","Coronary Artery Calcium Score in HIV Mexican Population (The CACsHIVMex Study)","CACsHIVMex","Inclusion Criteria:\n\n* Patients who have been diagnosed with HIV infection for more than 6 months\n* Undetectable viral load\n\nExclusion Criteria:\n\n* Patients who have previously taken statins\n* Patients with chronic ischemic heart disease that has required stenting or revascularization","ALL","18 Years",{"count":19,"type":20},384,"ESTIMATED","4 Years","OBSERVATIONAL","The risk of atherosclerotic cardiovascular disease is increased in people with HIV infection, including young patients and those with few traditional cardiovascular risk factors. The increased risk of cardiovascular disease among people living with HIV is due to accelerated atherosclerosis, caused by chronic inflammation and immune dysregulation. The measurement of coronary calcium using plain computed tomography is a subclinical indicator of coronary atherosclerosis and is associated with the risk of cardiovascular events and mortality in the general population.",[25],"HIV - Human Immunodeficiency Virus",[27,28,29,30],"coronary calcium","coronary calcification","cardiovascular risk","major adverse cardiovascular events","NOT_YET_RECRUITING","2026-06-18",{"date":34,"type":35},"2026-06-23","ACTUAL",{"date":37,"type":20},"2026-07-01",{"date":39,"type":20},"2030-07",{"name":41,"class":42},"Instituto Mexicano del Seguro Social","OTHER_GOV",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":65,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":43},"100637254","improving-the-hiv-care-continuum-with-mhealth-technology-100637254","NCT07631104","Improving the HIV Care Continuum With mHealth Technology","Improving the HIV Care Continuum for Youth in the Deep South Through Mobile Health Technology","Inclusion Criteria:\n\n* Between the ages of 16 and 25 years\n* Diagnosed with HIV\n* Resident of South Carolina\n* Proficient in English\n\nExclusion Criteria:\n\n* Under 16 years of age or over 25 years of age\n* Is not a person living with HIV\n* Is not a resident of South Carolina\n* Is not proficient in English","16 Years","25 Years",{"count":54,"type":20},40,"INTERVENTIONAL",[57],"NA","Youth living with HIV (YLHIV) face barriers to engagement and retention in HIV care, show poor medication adherence, and often fail to achieve and maintain viral suppression. YLHIV in the southern United States have particularly poor care engagement outcomes. South Carolina is one of nine states identified as \"key drivers\" of the US HIV epidemic, and HIV rates for youth in South Carolina have risen in recent years. Tailored interventions are urgently needed to improve outcomes for this population. One promising approach is to reach YLHIV via mobile Health (mHealth) technology, yet few efforts have sought to tailor mHealth interventions to the needs of YLHIV in the southern US. Thus, the scientific objective of this study is to pilot test a new mHealth intervention, called MindBodyU, designed to increase engagement\u002Fretention in care and ART adherence among YLHIV in South Carolina. In this study, investigators will evaluate the feasibility, acceptability, and initial efficacy of the mHealth intervention with a six-month pilot trial with 40 YLHIV in South Carolina.",[25,60,61,62,63,64],"HIV Antiretroviral Therapy (ART) Adherence","mHealth Application","mHealth Intervention","Continuum of Care","Youth With HIV",[66,67,68,69,70,71,72,73],"Youth living with HIV (YLHIV)","immunology","HIV","adolescents","emerging\u002Fyoung adults","eHealth\u002FmHealth\u002Fdigital health","adherence\u002Fself-management","psychosocial intervention","2026-06-02",{"date":76,"type":35},"2026-06-05",{"date":78,"type":20},"2026-06-01",{"date":80,"type":20},"2028-06-01",{"name":82,"class":83},"University of South Carolina","OTHER",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":55,"phases":94,"briefSummary":96,"conditions":97,"keywords":100,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":4},"100636004","phase-4-combating-related-epidemics-in-hcv-100636004","NCT07560046","Combating Related Epidemics in HCV","Combating Related Epidemics in HCV Through Simplified Testing and Treatment. A Cluster Randomized Trial of Point-of-care Hepatitis C Testing and Treatment Among Key Populations","CREST","Inclusion Criteria:\n\n1. Can provide written informed consent or assent\n2. Minimum of 16 years of age\n3. Willing to undergo HIV, HCV, HBV testing\n4. Willing to undergo treatment for HCV and complete study activities\n\nExclusion Criteria:\n\n1. History of HCV treatment for current infection\n2. Known preexisting (evidence or history of) decompensated liver disease based on: medical diagnosis through medical record, reporting by the participant, or clinical evidence per the site PI\n3. Contraindication for treatment with sofosbuvir\u002Fvelpatasvir due to allergy or drug-drug interaction including use of any prohibited concomitant medications within 28 days prior to study entry.\n4. History of clinically significant illness or any other major medical disorder that may interfere with participant treatment, assessment, or compliance with study requirements as determined by the site PI\n5. Ongoing need for use of daily proton pump inhibitor (PPI) at doses ≥40 mg of omeprazole (or equivalent). NOTE: PPI can be discontinued or dose reduced to 20 mg\u002Fday of omeprazole (or equivalent) at time of study entry.\n\nRetreatment Inclusion Criteria:\n\n1. Completion of sofosbuvir\u002Fvelpatasvir treatment regimen as enrolled participant in CREST and willingness to receive retreatment. FIB-4 \\& CTP score available within 90-days of retreatment initiation.\n2. Meeting any of the below criteria during post-cessation treatment follow-up. Relapse, defined as HCV RNA \\\u003CLLOQ\u002FD (TD or TND) during and\u002For at end of treatment followed by HCV RNA \\>LLOQ\u002FD or target detected based on qualitative POC test at any time point from end of treatment to 12 weeks after end of treatment OR Re-infection, defined as meeting the primary outcome criteria for SVR4+ followed by HCV RNA \\>LLOQ\u002FD or target detected based on qualitative POC test at any time point beyond meeting SVR4+ OR Post-treatment virologic failure, defined as HCV RNA \\>LLOQ\u002FD at any point after end of treatment (after week 24 visit) or during follow-up, not otherwise meeting definition of relapse or re-infection\n\nRetreatment Exclusion Criteria:\n\n1. Known preexisting (evidence or history of) decompensated liver disease based on: medical diagnosis through medical record, reporting by the participant, clinical evidence per the site PI, or by CTP score ≥7.\n2. Pregnant or breast feeding at time of retreatment with sofosbuvir\u002Fvelpatasvir\u002Fvoxilaprevir.\n3. Contraindication for treatment with sofosbuvir\u002Fvelpatasvir (reinfection) or sofosbuvir\u002Fvelpatasvir\u002Fvoxilaprevir (relapse or virologic failure) due to FDA package insert, allergy, or drug-drug interaction including use of any prohibited concomitant medications within 28 days prior to study entry.\n4. History of clinically significant illness or any other major medical disorder that may interfere with participant treatment, assessment, or compliance with study requirements as determined by the site PI\n5. Ongoing need for use of daily proton pump inhibitor (PPI) at doses ≥40 mg of omeprazole (or equivalent.). NOTE: PPI can be discontinued or dose reduced to 20 mg\u002Fday of omeprazole (or equivalent) at time of study entry.",{"count":93,"type":20},1280,[95],"PHASE4","This is a two-arm cluster randomized control trial to evaluate the effectiveness of a single-visit point-of-care (POC) test and treat bundle (intervention arm) compared to the current standard-of-care (SOC, control arm). 1:1 randomization occurs at the site level.",[25,98,99],"Hepatitis B Virus (HBV)","HEPATITIS C (HCV)",[101,102,68,90],"Hepatitis C","Hepatitis B","2026-04-30",{"date":105,"type":35},"2026-05-05",{"date":107,"type":20},"2026-08-01",{"date":109,"type":20},"2030-12-30",{"name":111,"class":83},"Duke University",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":55,"phases":121,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":138,"leadSponsor":140,"locationsCount":43},"100628252","ideas-for-hope-to-reduce-suicide-risk-and-improve-hiv-care-engagement-in-tanzania-100628252","NCT07459218","IDEAS for Hope to Reduce Suicide Risk and Improve HIV Care Engagement in Tanzania","IDEAS for Hope: A Brief Telehealth Intervention to Reduce Suicide Risk and Improve HIV Care Engagement in Tanzania","Inclusion Criteria:\n\n* Adult\n* Living with HIV\n* Attending HIV care appointments\n* Self-report experiencing thoughts of suicide in the last 30 days\n\nExclusion Criteria:\n\n* Physically or cognitively unable to provide informed consent or complete study procedures",{"count":120,"type":20},600,[57],"In this project, the investigators will conduct a clinical trial to test the effectiveness and implementation of IDEAS for Hope, a 3-session telehealth counseling intervention delivered by nurses, to reduce suicidality and improve HIV care engagement among PLWH in Tanzania. The investigators will also examine mechanisms of change and implementation outcomes of the intervention, including cost-effectiveness, to disseminate a feasible, scalable, and sustainable intervention and implementation package to address a critical mental health comorbidity in HIV care.",[25,124],"Suicide Prevention",[126,127,128,129,130,131,68,132,133],"task-shifting","task-sharing","stigma reduction","suicide prevention","health behavior","care engagement","telehealth","nurse-led intervention","2026-03-10",{"date":136,"type":35},"2026-03-12",{"date":107,"type":20},{"date":139,"type":20},"2031-06-30",{"name":111,"class":83},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":149,"sex":150,"minAge":4,"maxAge":4,"enrollmentInfo":151,"targetDuration":153,"studyType":22,"phases":4,"briefSummary":154,"conditions":155,"keywords":163,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":4},"100622850","magia-h3s-point-of-care-test-performance-for-hiv-hbv-hcv-and-syphilis-screening-in-pregnant-women-in-dr-congo-100622850","NCT07388979","MAGIA H3S Point of Care Test Performance for HIV, HBV, HCV, and Syphilis Screening in Pregnant Women in DR Congo","MAGIa In-vitro- Diagnostics Medical Device Dedicated to Combined Screening of HIV, HBV, HCV and Syphilis and HBV Reflective Panels aMong Congolese pregnAnt woMen Attending to Ante Natal Care Consultations","MAGICS MAM","Inclusion Criteria:\n\n* Being pregnant, regardless of age or stage of pregnancy (prenatal period);\n* Having signed an informed consent form at the start of prenatal care (CPN) to participate in the study.\n\nNote: for pregnant minors, the consent of a parent or legal guardian is required;\n\n* Have chosen to attend prenatal care at the healthcare facility selected for the study;\n* Plan to give birth at the same healthcare facility where they were included in the study;\n* Plan to attend postnatal care (PNC) and preschool consultations (PSC) at the same healthcare facility where they were included in the study.\n* Plan to give birth at the same health facility where they were enrolled;\n* Plan to attend postnatal consultations (PNC) and preschool consultations (PSC) at the same facility\n\nExclusion Criteria:\n\n* Women in labor or who refuse to give their consent.",true,"FEMALE",{"count":152,"type":20},7500,"12 Months","Performance study to evaluate the clinical performance of the In-Vitro Diagnostic Medical Device MagIA H3S (a Multiplex Point-of-Care test for the combined detection of Human Immunodeficiency Virus (HIV), Hepatitis B and C and Syphilis) from pregnant women attending antenatal care (ANC) services in the Democratic Republic of the Congo. This study aligns with the WHO 2022-2030 strategy for the integrated elimination of mother-to-child transmission of HIV, HBV, HCV, and syphilis.",[25,156,157,158,159,160,161,162],"HBV (Hepatitis B Virus)","Hepatitis C Virus (HCV)","Syphilis","Mother-to-Child Transmission","Performance","Point of Care STI Testing","TREAT B",[164,165,166],"Triple elimination","Mother-to-child transmission","Democratic republic of the Congo","2026-01-28",{"date":169,"type":35},"2026-02-05",{"date":171,"type":20},"2026-03-01",{"date":173,"type":20},"2027-12-21",{"name":175,"class":83},"Gardiens de Vies",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":149,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":55,"phases":186,"briefSummary":187,"conditions":188,"keywords":189,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":203},"100605250","phase-4-hiv-prevention-with-prep-among-people-on-opioid-replacement-therapy-100605250","NCT07160075","HIV Prevention With PrEP Among People on Opioid Replacement Therapy","Improving Access to HIV Pre-exposure Prophylaxis: Implementation and Evaluation of Innovative HIV Prevention Services Among Persons on Opioid Replacement Therapy in Western Canada: Prospective, Implementation Study","OAT-PrEP","Inclusion Criteria:\n\n* HIV negative\n* Ongoing behaviors with potential HIV exposure as assessed by a clinician\n* Regularly engaged with their respective OAT program at least 3 days a week for the past 2 weeks\n* Report willingness to return for follow-up visits\n\nExclusion Criteria:\n\n* Creatine clearance \\\u003C30 mL\u002Fmin or any medical condition or medication known to be contraindicated with the use of Emtricitabine\u002FTenofovir Alafenamide (F\u002FTAF) or Emtricitabine\u002FTenofovir Disoproxil Fumarate (F\u002FTDF)\n* Taken PrEP within the last 24 hours at the time of screening or enrollment\n* Deemed appropriate by a clinician for HIV Post-Exposure Prophylaxis at the time of screening or enrollment",{"count":185,"type":20},350,[95],"The purpose of this study is to assess the feasibility and acceptability of providing oral pre-exposure prophylaxis (PrEP) and opioid agonist therapy (OAT) simultaneously in existing pharmacy-based programs operating in Alberta and Saskatchewan, to collect preference, adherence, and persistence data on oral PrEP, and to assess interest \u002F acceptability of long-lasting injectable options for human immunodeficiency virus (HIV) prevention.",[25],[190,191,192,68],"PrEP","OAT","Opioid Agonist Therapy","RECRUITING","2025-10-01",{"date":196,"type":35},"2025-10-07",{"date":198,"type":35},"2025-08-28",{"date":200,"type":20},"2027-09-01",{"name":202,"class":83},"Cara Spence",6,{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":212,"enrollmentInfo":213,"targetDuration":4,"studyType":55,"phases":215,"briefSummary":217,"conditions":218,"keywords":221,"overallStatus":193,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":43},"100598719","phase-3-dortdf3tc-compared-with-bicftctaf-in-art-nave-people-living-with-hiv-and-overweight-or-obesity-100598719","NCT07075146","DOR\u002FTDF\u002F3TC COmpared With BIC\u002FFTC\u002FTAF in ART-Naïve People Living With HIV and Overweight or Obesity","Doravirine\u002FLamivudine\u002FTenofovir Disoproxil Fumarate COmpared With Bictegravir\u002FEmtricitabine\u002FTenofovir Alafenamide in ART-Naïve People Living With HIV and Overweight or Obesity","COATL","Inclusion Criteria:\n\n1. Adults (≥18 years) with confirmed HIV diagnosis, ART-naïve\n2. Signed informed consent\n3. HIV-1 RNA ≥1000 copies\u002FmL\n4. No history of PrEP or PEP failure\n5. BMI ≥25 kg\u002Fm² and body fat \\>20%\n6. Stable treatment for dyslipidemia (if applicable)\n7. No planned medication changes affecting weight\n8. Willingness to adhere to assigned ART\n9. Recent HIV-1 RNA and CD4+ results\n10. GFR (CKD-EPItip) ≥60 mL\u002Fmin\n11. ALT and AST \\\u003C90 IU\u002FL\n12. Willingness to report dietary or physical activity changes during follow-up Non-Inclusion Criteria\n\n1\\. Uncontrolled diabetes 2. Recent changes in insulin or hypoglycemic drugs (\\\u003C3 months) 3. Active malignancy 4. History of bariatric surgery 5. Allergies to study drugs 6. Hepatitis B and\u002For C coinfection 7. GFR \\\u003C60 mL\u002Fmin (CKD-EPI) 8. Drug interactions with ART regimens 9. Recent (60 days) use of anorectic drugs 10. Recent (30 days) hospitalization for severe illness 11. Unstable hypothyroidism\n\nExclusion Criteria:\n\n1. Loss of social security coverage\n2. Newly discovered allergy to study drugs\n3. Withdrawal of consent\n4. Hepatitis B or C infection acquired during follow-up\n5. Use of psychiatric or thyroid medications without a stable dose for ≥12 weeks\n6. Initiation or discontinuation of medications affecting weight after enrollment\n7. Unplanned bariatric surgery","70 Years",{"count":214,"type":20},306,[216],"PHASE3","Background:Historically, HIV infection was associated with significant weight loss. However, weight gain is now commonly observed after initiating antiretroviral therapy (ART), particularly in individuals underweight at baseline. It remains unclear whether this weight gain reflects a \"return to health\" or results from drug-related or metabolic effects, and whether it persists beyond immune restoration. Recent evidence indicates that ART regimens containing second-generation integrase strand transfer inhibitors (INSTIs), such as bictegravir combined with tenofovir alafenamide, are associated with greater weight gain compared to other antiretroviral combinations, raising concerns about potential long-term metabolic consequences.Objective:To evaluate the effectiveness, safety, and tolerability of Doravirine\u002FLamivudine\u002FTenofovir Disoproxil Fumarate (DOR\u002F3TC\u002FTDF) compared with Bictegravir\u002FEmtricitabine\u002FTenofovir Alafenamide (BIC\u002FFTC\u002FTAF) in ART-naïve people living with HIV (PWH) who are overweight or obese.Materials and Methods:This open-label, randomized clinical trial, approved by the Ethics and Scientific Research Committee (No. 3502), will be conducted at the Infectious Diseases Hospital of the National Medical Center \"La Raza\" from May 2025 to May 2027. ART-naïve PWH, recently diagnosed, with no prior use of pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP), who do not require hospitalization, and have a body mass index (BMI) ≥25 kg\u002Fm² and body fat \\>20%, will be invited to participate. Participants will provide written informed consent and be randomized 1:1 to receive either DOR\u002F3TC\u002FTDF or BIC\u002FFTC\u002FTAF.",[25,219,220],"Obesity","Overweight and\u002For Obesity",[68,222,223,224,225],"overweight","obesity","Doravirine","Bictegravir","2025-08-19",{"date":228,"type":35},"2025-08-24",{"date":230,"type":35},"2025-05-05",{"date":232,"type":20},"2028-08-01",{"name":234,"class":42},"José Antonio Mata Marín"]